Autopsy report · NCT05194839

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

“Due to safety findings in ongoing Phase 2 trials.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 2 months before it stopped.
• 79 participants enrolled.
• Results were posted on the registry 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Aristea Therapeutics, Inc.

Sponsor type

Industry

Conditions

Palmoplantar Pustulosis

Interventions

RIST4721; Placebo

Participants

79

Sites

51

Countries

Canada, Czechia, Germany, Hungary, Poland, United Kingdom, United States

Trials that died the same way

• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  “Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II portion.” (72% match in meaning)
• Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
  “Trial did not move to Phase II portion due to poor tolerance of treatment” (71% match in meaning)
• Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism
  “Lack of efficacy to proceed to Phase 2” (67% match in meaning)
• A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
  “The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.” (66% match in meaning)
• Safety of F14 Following Total Knee Replacement
  “Study superseded by alternative Phase 3 trial” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.